Skip to main content

Advertisement

Table 1 Some related clinical studies of RT combined with immunotherapy

From: Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

Authors Years Tumors Numbers of cases Immunotherapy RT Sequence of RT and immunotherapy Occurrence of abscopal effect
Roger et al. [157] 2018 Melanoma 25 Anti-PD-1 (pembrolizumab, 2 mg/kg/3 weeks or nivolumab, 3 mg/kg/2 weeks) 26 Gy/3–5 fractions Concurrent and post-radiation Observed
Formenti et al. [135] 2018 Metastatic breast cancer 23 Anti-TGFβ (fresolimumab,1 mg/kg/3 weeks or 10 mg/kg/3 weeks) 22.5 Gy/3 fractions Concurrent Observed
Rodríguez-Ruiz et al. [136] 2018 Advanced cancer 15 DC vaccination and TLR-3 agonist Stereotactic ablative RT Concurrent Observed
Aboudaram et al. [130] 2017 Melanoma 17 Anti-PD-1 (pembrolizumab, 2 mg/kg/3 weeks or nivolumab, 3 mg/kg/3 weeks) 30 Gy/10 fractions Concurrent Observed
Theurich et al. [158] 2016 Melanoma 45 Anti-CTLA-4 (ipilimumab, 3 mg/kg/3 weeks) SBRT Concurrent and post-radiation Observed
Koller et al. [119] 2016 Melanoma 70 Anti-CTLA-4 (ipilimumab, 3 mg/kg/3 weeks) Conventional external beam radiation and stereotactic radiosurgery Concurrent Observed
Twyman-Saint et al. [145] 2015 Melanoma 22 Anti-CTLA-4 (ipilimumab) Lung/bone 8 Gy × 2 or 8 Gy × 3
Liver/subcutaneous 6 Gy × 2 or 6 Gy × 3
RT before ipilimumab Observed
Golden et al. [107] 2015 Metastatic solid tumors 41 GM-CSF (125 μg/m2/2 weeks) 35 Gy/10 fractions Concurrent Observed
Grimaldi et al. [118] 2014 Melanoma 21 Anti-CTLA-4 (ipilimumab, 3 mg/kg/3 weeks) RT of brain metastasis or extracranial sites RT after ipilimumab Observed
Hwang et al. [159] 2018 Metastatic lung cancer 164 Anti-PD-1/PD-L1 Thoracic RT RT before or after immunotherapy Non-observed
Shaverdian et al. [129] 2017 NSCLC 97 Anti-PD-1 (pembrolizumab, 2 mg/kg/3 weeks, 10 mg/kg/3 weeks, or 10 mg/kg/3 weeks) Extracranial radiotherapy and thoracic radiotherapy Ipilimumab after RT Non-observed
Kropp et al. [160] 2016 Melanoma 16 Anti-CTLA-4 (ipilimumab, 3 mg/kg/3 weeks) SBRT RT after ipilimumab Non-observed
Levy et al. [133] 2016 Metastatic tumors 10 Anti-PD-L1 (durvalumab, 10 mg/kg/3 weeks) 28 Gy/5 fractions (median) Concurrent Non-observed
Kwon et al. [121] 2014 Castration-resistant prostate cancer 799 Anti-CTLA-4 (ipilimumab, 10 mg/kg/3 weeks) 8 Gy/target bone lesion Ipilimumab after RT Non-observed
Slovin et al. [120] 2013 Castration-resistant prostate cancer 50 Anti-CTLA-4 (ipilimumab, 10 mg/kg/3 weeks) 8 Gy/target bone lesion Concurrent Non-observed
  1. RT radiotherapy, NSCLC non-small cell lung cancer, GM-CSF granulocyte-macrophage colony-stimulating factor, SBRT stereotactic body radiotherapy